Tarsons products reports steady growth, strategic expansion in FY 2024-25

Tarsons Products Limited recorded standalone revenue from operations of INR 3,141.77 million for FY 2024-25, up from INR 2,773.10 million in the previous year. The company's EBITDA (excluding foreign exchange fluctuation loss/gain and other income) for the period was INR 1,054 million, with a PAT of INR 427.31 million. Consolidated revenue reached INR 4,083.74 million, with a consolidated PAT of INR 297.70 million. The company also reported a net worth of INR 6,523.89 million.

Strategic initiatives in FY 2024-25 included partial commercial production at the Panchla facility and progress in developing the Amta integrated radiation plant and fulfillment center, both expected to ramp up in H2 FY 2025-26. These expansions aim to boost cell culture and bioprocessing product lines, enhancing automation and cost efficiency. The acquisition of German entity Nerbe expanded the company's European presence.

The board of directors has not recommended a final dividend for FY 2024-25, opting to retain profits for future opportunities and sustainable growth. The company spent INR 20.89 million on CSR activities, primarily through a donation to Tata Medical Centre.